Want to find your lens? Five questions, no jargon — they tell you which of four reads fits how you already think.
We can't give an honest read on this one right now.
Our model values a company on the cash it can hand its owners after paying for its own growth. For Baxter that number is not something we can compute today — so rather than estimate around the gap, we are leaving it blank until the next filings close it.
Why not
- Caution: What is missingBaxter sold its Vantive kidney-care business — roughly a third of its revenue — to Carlyle in February 2025, and its newest annual report, for 2024, still consolidates it. Our fair value is built from typical free cash flow over five years, so the base it would use describes a Baxter a third larger than the one that trades. The 2025 annual report is the first without Vantive; a five-year base that reflects the change is several filings further out.
Why show the page at all. Because the alternative is a number we don't believe. Every other company on TickerMath gets a fair value computed from its SEC filings; this one gets a plain explanation instead, which is the same promise kept a different way. This one is expected to change: we re-test every company against its new filings, and the read appears here as soon as the figures support it.
TickerMath is an educational tool, not investment advice — it computes one model from SEC filings and can be wrong. How we compute this →